This is a category taken from the full feed of Musculoskeletal and Arthritis news provided by ARMA's members.

Resources

ARMA BOA BSR RAIRDA

Principles for COVID-19 Vaccination in Musculoskeletal and Rheumatology for Clinicians

(Version 1, 14th January 2021)

All patients should be encouraged to receive one of the COVID-19 vaccines. This is regardless of their treatment regimen or underlying diagnosis. The benefits of the COVID-19 vaccination outweigh the risks and by having the vaccine, this will reduce the risk of developing severe complications due to COVID-19. Vaccinations will be offered in line with the prioritisation criteria from the Joint Committee for Vaccination and Immunisation (JCVI) (please see the prioritisation section below).

We are receiving a large volume of calls from patients to our departmental advice and patient charity advice lines about the suitability and timing of the COVID-19 vaccines. It is important that we try to provide the same advice where possible.

This is a working document and it will be updated as new information/data becomes available.

The following principles may help us to achieve this:

AVAILABLE VACCINATIONS

1. There are a number of different vaccinations under development, and as of 11th January 2021 three have been approved for use by the MHRA. The table below lists these vaccines. The table will be updated as needed.

2. None of the current UK approved vaccines are considered to be ‘live’ vaccines. The vaccines are considered safe for use in immunosuppressed patients. Whether any new future vaccine is categorised as ‘live’ or not will need to be reviewed for each vaccine as it is authorised by the MHRA by looking in the summary product characteristics (SPC) document for the product. The Oxford/AstraZeneca vaccine contains a live adenovirus vector but is non-replicating so cannot cause infection and is therefore safe for people who are immunosuppressed.

3. The Pfizer/BioNTech COVID-19 mRNA Vaccine BNT162b2 has been approved for use in individuals 16 years of age and older by the MHRA and is being rolled out. The Oxford/Astra Zeneca (ChAdOx1 nCoV-2019 vaccine) was approved by the MHRA for use on 30th December 2020 and roll out started on 4th January 2021. The Moderna vaccine was authorised for use on 8th January 2021 and will be rolled out in the coming months.

 

[This table has five columns – scroll right]

Vaccine name Live or not live
(MHRA classification?)
Date approved by MHRA Approved for Dose
administration
Pfizer/BioNTech COVID-19 mRNA Vaccine BNT162b2 Not live 03/12/2020 16 years and older 2 doses up to 12 weeks apart
Oxford/Astra Zeneca (ChAdOx1 nCoV-2019) vaccine Not live* 30/12/2020 18 years and older 2 doses up to 12 weeks apart
Moderna  Not live 08/01/2021 18 years and older 2 doses

*This vaccine contains a live adenovirus vector but it is non-replicating so cannot cause infection and is therefore safe for people who are immunosuppressed.

4. The environment used for the administration of the vaccine should be as safe as possible for patients and staff and should adhere to the principles of social distancing and use of appropriate levels of PPE

SAFETY

5. Cautions are the same for patients as for the general population:

  • A very small number of individuals have experienced anaphylaxis when vaccinated with the Pfizer BioNTech vaccine. Following close surveillance of the initial roll out, the MHRA has advised that individuals with a history of anaphylaxis to any vaccine, medicine or food, can receive any COVID-19 vaccine as long as they are not allergic to any component (excipient) of the vaccine. The Pfizer/BioNTech COVID-19 vaccine contains polyethylene glycol (PEG), which is from a group of known allergens commonly found in medicines and also household goods and cosmetics. Known allergy to PEG is extremely rare but would contraindicate receipt of this vaccine. Of note certolizumab pegol contains PEG so patients who have had an allergic reaction to certolizumab pegol should not receive the Pfizer/BioNTech vaccine. PEG is also an excipient in the Moderna mRNA COVID-19 vaccine; individuals who have a systemic allergic reaction to the Pfizer-BioNTech vaccine should not be given a dose of the Moderna vaccine and vice versa. The British Society for Allergy and Clinical Immunology has advised that individuals with a history of immediate onset anaphylaxis to multiple classes of drugs or unexplained anaphylaxis should not be vaccinated with the Pfizer BioNtech vaccine. The AstraZeneca vaccine can be used as an alternative (if not otherwise contraindicated).
  • The vaccines should not be administered to individuals suffering from an acute severe febrile illness.
  • Patients should continue to perform social distancing/shield after their vaccination.

6. The Pfizer/BioNTech COVID-19 mRNA Vaccine BNT162b2 and Oxford/Astra Zeneca (ChAdOx1 nCoV-2019 vaccine) vaccines are safe for immunocompromised persons, as they are not live vaccines. Frequently, the immune response of immunocompromised persons to these vaccine antigens is not as good as that of immunocompetent persons. Immunocompromised persons include individuals receiving immunosuppressant therapy, including corticosteroids. Detailed information and data about the efficacy of COVID-19 vaccination in the immunosuppressed are not yet available but national studies are already underway to answer this.

VACCINATION OF THE CLINICALLY EXTREMELY VULNERABLE POPULATION

7. Clinically extremely vulnerable people are expected to receive a vaccination against COVID-19 before the general population. The local NHS will ensure that they receive the vaccine as safely as possible, as well as any care and support needed. Patients that have had both doses of the vaccine, they should continue to follow this shielding advice, until further notice as we continue to assess the impact of vaccination among all groups. The people they live with should continue to follow the public health rules and guidance as long as they are in place, including if the CEV person has received the vaccine and also if they have received the vaccine.

INTERACTION WITH ONGOING TREATMENT  

8. Patients should not stop their immunosuppression.

9. It is known that some drugs e.g. rituximab reduce the response to some vaccines such as the seasonal flu vaccine. It is anticipated that patients receiving rituximab may potentially have a reduced response to the COVID-19 vaccines. It may not be possible to time the administration of the vaccine with the course/start of immunosuppression treatment. The benefits versus the risks need to be considered and discussed with the patient and a shared decision made. Patients are still advised to receive the COVID-19 vaccine.

10. Considerations regarding the use of Rituximab :

Ideally, and based on advice from Roche, the manufacturer of the rituximab originator drug, a pulse of rituximab should be given at least 4 weeks after a dose of the COVID-19 vaccine (personal communication). Second doses of COVID-19 vaccine are going to be delayed up to 12 weeks after the first dose, which adds an additional layer of logistical complexity.

The following should be considered:

  1. Rituximab should not be delayed in patients with acute severe organ-threatening multi-system disease who need urgent treatment to control their disease. In this scenario, treatment with rituximab and the concurrent administration of the vaccination should go ahead regardless of timings i.e. as soon as they are available.
  2. If a patient needs to start a new DMARD/biologic but has not been vaccinated, it may be appropriate to consider selecting an alternative DMARD / biologic medication to rituximab, if available and appropriate, e.g. in patients with rheumatoid arthritis.
  3. For patients receiving non-urgent/maintenance rituximab, consider deferring a rituximab course until 4 weeks after a dose of the COVID-19 vaccine, if clinically possible.

The following summarises the advice for the likely scenarios:

  • If a patient has been offered a date for vaccination, then vaccinate and delay rituximab for four weeks.
  • If vaccine is available now for the patient but patient is still B-cell depleted on rituximab, then do not delay vaccination until B-cells recover but vaccinate now. There is no evidence to suggest how long after a pulse of rituximab a patient should delay vaccination with the COVID-19 vaccine but consensus suggests this should ideally be 4-8 weeks after rituximab if it is ok to defer the COVID-19 vaccine. This decision may depend upon the prevalence of COVID-19. A shared decision should be made with the patient.
  • If vaccine is not available now for the patient, and it’s not safe to delay rituximab for four weeks g. because of organ threatening disease, then give rituximab without delay and vaccinate whenever vaccine is available
  • If vaccine is not available now, and it is safe to delay rituximab or to switch to an alternative treatment, then consider these options. A shared decision should be made with the patient. 

11. Corticosteroids: oral, intra-articular, intra-muscular or IV and timing of the COVID-19 vaccination

There are some general principles but in each case the benefits and risks should be discussed with the patient to arrive at a shared decision:
• It is safe to have the COVID-19 vaccine alongside steroid exposure, but the patient may not mount such a good immune response.
• Do not delay vaccination for someone who is taking, has received or is soon to receive steroids in any form.
• If additional steroids are required to control inflammatory disease, that may take priority, as a flare can also worsen the risk from COVID-19
• It may be appropriate to delay a non-essential steroid injection, as part of a shared decision, so that the response to the vaccine is more effective. For a patient who is on an elective waiting list for a steroid injection of up to 80mg methylprednisolone or 80mg triamcinolone, the administration of the COVID-19 vaccine is the priority if the vaccine has been offered to the patient and the prevalence of COVID-19 is high. In this scenario, the steroid injection should be deferred by 2 weeks after the vaccine, to enable the patient to mount the best response to the COVID-19 vaccine.

PRECAUTIONS AND CONTRAINDICATIONS

12. Pregnancy: The available data for the Pfizer-BioNTech and AstraZeneca COVID -19 vaccines do not show any safety concerns or harm to the mother or baby during pregnancy. However, there is insufficient evidence to recommend routine use of the vaccines during pregnancy. Routine pregnancy testing before administration of the vaccine is not required. However, vaccination during pregnancy should be considered if there is a high risk of exposure to SARS-CoV2 infection or if the pregnant woman has underlying conditions that put them at very high risk of serious compilations if they develop COVID-19. In these circumstances, clinicians should discuss the risks and benefits of vaccination with the woman, who should be told about the absence of safety data for the vaccine in pregnancy. Termination of pregnancy following inadvertent immunisation should not be recommended.

13. Breastfeeding: There is no known risk associated with giving non-live vaccines whilst breastfeeding. The JCVI advises that breastfeeding women may be offered vaccination with the Pfizer-BioNTech or AstraZeneca COVID-19 vaccines, following a discussion about the developmental and health benefits of breastfeeding along with the mother’s clinical need for immunisation against COVID-19, and the woman should be informed about the absence of safety data for the vaccine in breastfeeding women.

14. Elective surgery: It is recommended that people undergoing elective surgery have 7 days between the vaccination and surgery (both before and after surgery). This applies to both doses of the vaccine. The rationale for separating the date of surgery from vaccination is so that any symptoms such as fever post vaccination might be correctly attributed to the consequences of either vaccination or the operation itself. People underdoing elective surgery who have been vaccinated are still asked to self-isolate prior to surgery and take a COVID test before surgery.

15. Urgent/emergency surgery: For those requiring urgent/emergency surgery, surgical intervention should proceed.

PRIORITISATION

The following table outlines the priority groups for vaccination as advised by the JCVI:

Priority group  
1

Residents in a care home for older adults

Staff working in care homes for older adults

2

All those 80 years of age and over

Frontline Health and social care workers

3 All those 75 years of age and over
4

All those 70 years of age and over

Clinically extremely vulnerable individuals (not including pregnant women and those under 16 years of age)

5 All those 65 years of age and over
6

Adults aged 16 to 65 years in an at-risk group

7 All those 60 years of age and over
8 All those 55 years of age and over
9 All those 50 years of age and over

 

16. All clinicians should continue to identify patients who are at the highest risk from COVID-19 (the Clinically Extremely Vulnerable (CEV)), and submit their details to NHS Digital, so that they can be added to the shielded patients list (SPL). All NHS Trusts have a mechanism to do this. Decision-support tools to help identify these patients are available on the British Society for Rheumatology’s (BSR) website. This is guidance, and ultimately the decision to submit patient details to NHS Digital/add a person to the SPL list will be made on a case by case basis.

17. At the present time, it is not possible to deliver the vaccine to all patients with urgent clinical need e.g. patients who are due a pulse of rituximab in the next couple of months. This may be something that is possible in the future as logistics become easier. Clinicians may be able to recommend that a patient should receive a vaccination at a specific time to optimise response according to treatment schedule by contacting their local vaccination hub e.g. for a small number of patients receiving non-urgent/maintenance rituximab as outlined in point 9. We will continue to have discussions about the logistics of trying to deliver this pragmatic approach with NHS England and will update the document accordingly.

FURTHER QUESTIONS

The data and evidence regarding the safety and effectiveness of the COVID-19 vaccines continues to emerge. Many unanswered questions remain but data are being collected to try to answer these questions.

These questions include:

  • ‘How long does the vaccine last/ what is the duration of immunity?’
  • ‘Should methotrexate be suspended temporarily around the time of the COVID-19 vaccine?’

This document will be updated as new evidence emerges to answer these and other current pertinent questions.

REFERENCES

JCVI website:
https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation

Green book chapter 14a COVID-19- SARS-CoV-2:
https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948517/Information_for_Healthcare_Professionals_on_Pfizer_BioNTech.pdf

BSR website: https://www.rheumatology.org.uk/covid-19/

Versus Arthritis website: https://www.versusarthritis.org/news/2020/april/coronavirus-covid-19-and-arthritis-where-to-go-for-information/

Decision Support Tool: https://www.versusarthritis.org/media/23183/msk-rheumatology-decision-support-tool-covid-19-vaccines-final-15012021.pdf

Royal College of Obstetricians and gynaecologists: https://www.rcog.org.uk/en/news/covid-19-vaccination-and-pregnancy/

Acknowledgements

We are grateful to the members of the NHS England and NHS Improvement musculoskeletal stakeholder group led by National Clinical Director for Musculoskeletal, the specialised rheumatology clinical reference group, the Behaviour Change Unit and the British Society for Rheumatology COVID group, for their input and review of the different iterations of this draft document.

Campaign Resources
The Covid-19 vaccine will be one of the best ways of protecting yourself and starting to get back on the path to normality. Healthcare workers, social care workers and care home staff will get the free, MHRA approved vaccine.

Resources for the campaign are available on the Campaign Resource Centre to be shared across your channels and networks locally. These include: posters, Social animations, Social statics, additional Social, email signatures.

Updated guidance was published in December to support primary and community care practitioners in recognising serious pathology which requires emergency or urgent referral to secondary care in people with new or worsening MSK symptoms. Serious pathology as a cause of MSK conditions is considered rare, but it needs to be managed either as an emergency or as urgent onward referral as directed by local pathways. Any part of the MSK system can be affected.

Emergency conditions are serious pathologies which must be dealt with on the day as an emergency. The guidance highlights the need to keep updated on pathways for emergency referral in the local system. It sets out the symptoms to look out for in Cauda equina syndrome, Metastatic spinal cord compression, Spinal Infection, Septic arthritis, and Giant Cell Arteritis as well as for a range of conditions which require an onward urgent referral.

Find the full guidance on the ARMA Resources page.

 

Last month, NHS England and NHS Improvement launched the ‘Help Us Help You – NHS Access’ campaign which looks to address the barriers that are deterring patients from accessing NHS services.

Since then, the mental health phase of the campaign has launched, aiming to increase awareness of NHS talking therapies services (IAPT). It will encourage adults with mental health issues such as anxiety or depression to seek help and consider accessing talking therapy via their GP or through self-referral. Campaign resources including posters, social media assets and a social calendar are available on the Campaign Resource Centre.

The NASS Facebook Live sessions have been running since March, helping people to manage their axial SpA (AS) in these unprecedented times and beyond. All of these sessions are available live, allowing comments and questions to be answered. Check the NASS Facebook events page for details of upcoming sessions.

The sessions are also recorded and form part of ‘My AS My Life’ – a new self-management hub on the NASS website.

The A2E deadline has been extended

The Aspiring to Excellence programme 2020 will now close to applications on 18 September 2020.

New2RA Right Start

The NRAS New2RA Right Start service supports people newly diagnosed with Rheumatoid Arthritis to understand their diagnosis and how it is likely to affect them. Getting the right, supportive start can help people to make adjustments to their behaviour, lifestyle and health beliefs and understand why self-management is essential, and learn how to make those important first steps to managing their disease effectively.

Further information can be accessed on the NRAS New2RA Right Start service page. This service is essential during this time for those newly diagnosed during the COVID-19 crisis, offering extra support when appointments are being delayed.

NRAS Website chatbot

The National Rheumatoid Arthritis Society (NRAS) and earthware are pleased to announce a partnership to deliver a new patient-support chatbot.

The chatbot will be available on the NRAS website and will help answer questions from its visitors, ensuring easier navigation to information available. For more information visit the NRAS partnership press release.

The Faculty of Sport and Exercise Medicine (UK) has updated their Staying Active at Home resources to include a series of short videos introducing some simple exercises that can be carried out at home, and which are particularly suitable for people who are older or have long-term health conditions. They include exercises that can be performed while sitting, standing, walking or lying down, and were produced with the help of Pure Sports Medicine.

You can watch the videos on our Youtube channel, or find the full set of Staying Active at Home resources on the FSEM website.

People with fibromyalgia are finding themselves wondering whether they are more at risk of getting Coronavirus, as are other chronically ill and healthy people. The lack of clarity over the origin of our condition does not help in these circumstances. The government uses broad categories to inform people and control risk to vulnerable people. But these broad categories are collecting people and inflaming their anxiety, which does not help their chronic condition.

FMA UK has created a webpage that will be regularly updated to point to latest government guidelines and specific information for people with fibromyalgia. Fibromyalgia does not fall under the specific risk groups on its own because it is not an autoimmune condition or degenerative neurological condition. However, people who contract this virus will most likely have a worse time of it than a healthy person if they have more than a mild case.

For fibromyalgia and coronavirus information please visit this page: https://www.fmauk.org/coronavirus.